Same Drug Class

Nivolumab vs Osimertinib

Nivolumab vs Osimertinib: Overview

This comparison examines the pharmacological differences between Nivolumab and Osimertinib.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.

Pharmacokinetics

Half-life: Nivolumab β€” 27 days; Osimertinib β€” 48 hours.

Chemical Properties

Molecular Formula: Osimertinib β€” C28H33N7O2.

Molecular Weight: Osimertinib β€” 499.6050 g/mol.

Type: Nivolumab β€” Antibody; Osimertinib β€” Small molecule.